Pharmaceutical Executive

How Can Pharma Navigate the Regulatory Maze of AI-Powered Interventions?

December 6th 2024

The latest news for pharma industry insiders.

Peer Exchange: Embracing AI in Pharma

December 6th 2024

Trinity Life Sciences Releases Annual TGaS Digital Marketing Competency Report

December 6th 2024

FDA Accepts Roche’s Supplemental Biologics License Application of Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 6th 2024

$FDA Accepts Roche’s Supplemental Biologics License Application of Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Vaccines After COVID: Biopharma's Renewed Public Health and Commercial Push

December 5th 2024

Powering Pipelines Forward: Approach Science Differently

Why tapping the value generated for the next set of therapies is critical.

Visit Now

Conference Coverage

View All

Financial Times Global Pharma and Biotech Summit: The Impact of the Election

November 8th 2024

Strategies for the Looming Pharma Patent Cliff

November 7th 2024

Financial Times Global Pharma and Biotech Summit: Taking Action on Innovation in Europe

November 7th 2024

FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer

November 7th 2024

All News

Adoption Lag in AI: Q&A with Scott Snyder

Approval of Imfinzi was based on results from the ADRIATIC Phase III trial, marking the first systemic immunotherapy available for limited-stage small cell lung cancer.

Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more

EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.

The Ethical Implications of AI-Driven Patient Engagement

The latest news for pharma industry insiders.

FDA Grants Breakthrough Therapy Designation to Allay’s Therapy for Post-Surgical Pain in Total Knee Arthroplasty

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explores the ethical implications of using AI to collect and analyze patient data, and improve outcomes.

Eli Lilly’s Zepbound Demonstrates Superior Weight Loss to Wegovy in Adults With Obesity or Overweight

The breakthrough designation is based on Phase II clinical trial data, which demonstrated that ATX101 provides sustained pain relief for up to four weeks following total knee arthroplasty.

Lil Jon Teams With Exact Sciences to Promote Colon Cancer Screening

Results from the SURMOUNT-5 Phase IIIb trial found that Zepbound achieved an average weight loss of 20.2%, surpassing Wegovy’s 13.7%.

Pharma Pulse 12/4/24: Streamlining Clinical Data Exhaust, T1D Impact on Children's Brain Development & more

The musician launched the Get Low #2 campaign.

The Data Behind Cancer Research: Q&A with Alicia Zhou

The latest news for pharma industry insiders.

Personalized AI-Powered Solutions for Better Patient Adherence

The non-profit’s new CEO discusses her role and how she plans to steer the organization towards the future.

FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for Metastatic Nonsquamous Non-Small Cell Lung Cancer

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, identifies how AI can identify patients at risk of medication non-adherence and intervene early to prevent negative outcomes.

Takeda, Novartis, and Gilead Strike Separate Licensing Deals

The breakthrough designation is based on data from the expansion cohort of a Phase I/II study evaluating sacituzumab tirumotecan in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

John Hancock to Provide Apple Watches to Eligible Customers

Licensing deals are expected to enhance the oncology, neuroscience, and antibody drug conjugate pipelines of the three manufacturers.

Using AI to Predict and Influence Patient Behavior

The devices are being provided based on a variety of health-based features that they provide.

BGM and AIX Announce Acquisition Agreement

In this part of his Pharmaceutical Executive video interview, Bill Grambley, CEO of AllazoHealth, explains how AI can be leveraged to create highly personalized patient engagement strategies, tailored to individual needs and preferences.

Pharma Pulse 12/3/24: Shaping the Future of Commercialization, Looming PREP Act Expiration Could Impact Rural Patients & more

AIX exchanged key assets in exchange for ownership shares.

FDA Accepts GSK’s Biologics License Application of Blenrep for Relapsed or Refractory Multiple Myeloma

The latest news for pharma industry insiders.

$FDA Accepts GSK’s Biologics License Application of Blenrep for Relapsed or Refractory Multiple Myeloma$

Roche Inks Deal to Acquire Poseida Therapeutics

December 2nd 2024

Acceptance of the Biologics License Application of Blenrep was based on promising results from the DREAMM-7 and DREAMM-8 Phase III trials in patients with relapsed or refractory multiple myeloma.

Pharma Pulse 12/2/24: Retooling the ‘Gene’ Value Machine & more

December 2nd 2024

Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases.